Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LycoRed enters infant formula market

This article was originally published in The Tan Sheet

Executive Summary

LycoRed announces Nov. 20 the launch of a line of "advanced oily blends featuring proprietary fatty acid premixes" designed for use in infant formula. The oily blend contains a "custom made composition of long chain polyunsaturated fatty acids and other oily soluble ingredients," the firm says. Product manufacturing will be at LycoRed's "new specialized lipid formulation facility" in the UK, the firm says. LycoRed Managing Director Peter Gallagher says, "Our goal is to penetrate this market with hot, new lipids that will allow manufacturers to create healthy and cutting-edge products. Investment in our premix facilities is the cornerstone of our strategy." LycoRed is the "leading European manufacturer for innovative premixes" and entered the U.S. premix market in July, according to a release...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099983

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel